Paolo Ciraci

Pisa, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Distinct molecular and clinical aggressiveness in very early-onset metastatic colorectal cancer: survival and genomic divergence between patients aged 30-39 versus 40-49 years.

Distinct molecular and clinical aggressiveness in very early-onset metastatic colorectal cancer: survival and genomic divergence between patients aged 30-39 versus 40-49 years.

Journal: ESMO open
Published: February 02, 2026

The Impact of Surgical Resection in Early Onset Colorectal Cancer Patients With Liver Limited Disease.

The Impact of Surgical Resection in Early Onset Colorectal Cancer Patients With Liver Limited Disease.

Journal: Clinical colorectal cancer
Published: November 24, 2025

Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO.

Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 05, 2025

Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients.

Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients.

Journal: ESMO open
Published: June 18, 2025

The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.

The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.

Journal: European journal of cancer (Oxford, England : 1990)
Published: January 30, 2025

Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study.

Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study.

Journal: ESMO open
Published: December 02, 2024

KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration.

KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration.

Journal: JCO precision oncology
Published: November 07, 2024

Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm.

Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm.

Journal: Nature reviews. Clinical oncology
Published: October 25, 2024

Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon.

Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon.

Journal: British journal of cancer
Published: August 31, 2024

Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer. A systematic review and pooled analysis from phase II and III trials.

Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer. A systematic review and pooled analysis from phase II and III trials.

Journal: Cancer treatment reviews
Published: August 10, 2024

A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer.

A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer.

Journal: Cancer cell
Published: April 05, 2024

Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset.

Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset.

Journal: ESMO open
Published: February 15, 2024
Showing 1-12 of 17

Last Updated: 09/26/2026